TREATMENT OF ADVANCED PARKINSON'S DISEASE WITH A SUSTAINED-RELEASE PREPARATION OF L-DOPA

B. Kleedorfer, G. Birbamer, G. Randmayr, W. Poewe and F. Gerstenbrand

Universitätsklinik für Neurologie, Anichstr. 35, 6020 Innsbruck, Austria.

INTRODUCTION

About 50 per cent of patients with Parkinson's disease develop a fluctuating response to chronic treatment with conventional L-Dopa preparations (Marsden et al, 1982; Marsden, 1976). Based on the findings that these fluctuations can be compensated by constant-rate intravenous infusions of L-Dopa (Quinn et al, 1984) oral sustained-release preparations have been developed to obtain stabilization of L-Dopa plasma levels. Following initial positive results with oral sustained-release L-Dopa (Madopar HBS) (Poewe et al, 1986) we have carried out an open trial with Madopar HBS.

PATIENTS AND METHODS

Il patients with advanced Parkinson's disease and a fluctuating response to long-term treatment with conventional L-Dopa were included in this trial. Their clinical data are summarized in Table 1.

Table l	Madopar HBS in advanced P.D./patient data
N= ll Age Duration	6 male, 5 female 59,8 (51-76) years
- Disease - L-Dopa Hoehn and Yahr Stage	9,8 (5~19) years 6,0 (2-14) years
- "on" - "off"	2,1 4
L-Dopa dose	700 (350-1700) mg

In an in-patient phase of 2 to 4 weeks the response characteristics to their individual L-dopa regimen was assessed using self-scoring onoff diaries for hourly documentation of on-off swings as well as involuntary movements (AIM's) (see figure 1). In addition, Parkinson's disease symptoms were rated weekly during "on" and "off" phases using+.

OF C = NGNE C = NGNE C = NGNE T = NLO Sept. 315 INTERMEDIATE I = NLO I = NLO I = NLO Sept. 315 SLEEP MADDRA STANDAD I = NLO I = NLO ANTE 1 = 1 2 = 2 2 = NLO I = NLO I = NLO ANTE 1 = 2 2 = 4 5 7 1 = NLO I = NLO ANTE 1 = 2 2 = 4 5 7 1 = NLO I = NLO ANTE 1 = 2 2 = 4 5 7 1 = NLO I = NLO ANTE 1 = 2 2 = 4 5 7 1 = NLO I = NLO ANTE 1 = 2 2 = 4 5 7 1 = NLO I = NLO ANTE 1 = 2 2 = 4 5 7 1 = NLO I = NLO ANTE 1 = 2 2 = 4 5 7 1 = NLO I = NLO ANTE 1 = 2 2 = 1 7 7 7 1 = NLO NOT 0 0 0 0 0 0 1 1 1	m	MORILITY										0	1	SKIN	DYSKINCLIA					9	19470-9-0-ND	1	191			
ANDERATE INTERMEDIATE INTERMEDIATE <th <="" colspan="2" th=""><th></th><th></th><th>0FF</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th>e N</th><th>ON E</th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th><th></th></th>	<th></th> <th></th> <th>0FF</th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th>e N</th> <th>ON E</th> <th></th>				0FF										e N	ON E										
27 22 24 35 5 7 38 9 10 11 12 13 14 15 1 2 3 5 5 7 38 9 10 11 12 13 14 1 2 3 4 5 5 7 38 9 10 11 12 13 14 1 10 0	Aug. MONTH Sept	38	IN TE Slee	EP EP	MADO	PAR	STAN	DARD				- 11 (1	5. 5. UI	COER COER EVER	เน เ− ≪เนย		2	000	44	S an						
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	DATE	21	22		7	-	25	26	4	-		-	2	7	-	15	4	<u> </u>	4	7	5	-				
a b b b	DAY	-	2	m	4	-	5	ø,	_	~			80	σ		10	1	-	-	5	4	-				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		_	m		10	-		1 mars		0	-	-			-		-	-	a	100	-	-	n	1.00		
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	TIME	0		11		0	0	0	11	0	-	2	0	2.5	0	0	5			5	5	-				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	orning					0 11	0	11110	111	0			0		0		5	1111		1		-				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		1	11	11		0	2	1	_	+		-	٢		1	5	11	-	2	5	11			1		
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	0	0			11	0 11	-	1	-	0	-	-			0	1	14		5	1		-				
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	1 01	0////	10			0	0	0		0	-	-	1.1.1		0 11		12		5	5		-				
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		6				1	0	0 1		7			0	-	1	0	F	-	0	5	0					
$ \begin{bmatrix} 1 & 0 & 0 & 1 \\ 2 & 2 & 0 & 2 \\ 0 & 0 & 2 \\ 0 & 0 & 2 \\ 0 & 0 & 0 \\ 1 & 0 \\ 1 & 3 \\ 0 & 1 \\ 0 & 0 \\ 1 & 3 \\ 0 & 1 \\ 1 & 0 \\ 1 & 0 \\ 1 & 0 \\ 1 & 0 \\ 1 & 0 \\ 1 & 0 \\ 0 & 0 \\ 1 & 0 \\ 0 & 0 \\ 1 & 0$		0 11	1		11	0	0	0		0	-	-	٢	·	6	0	1	-	0	5		-				
2 2 2 2 0	ternoo			111		1	٢	0		7	-	_	٢	5	-	0	1	-	-	1	0					
0 0 2 00 0		2			-	2 11	0	0 11		7		-	0	5			0	1	10	0 11	0					
1 3 0 0 1 0 0 1 0		0				11 0	10	10		0			0	5	11 0		0	227	0	0 11	0	-				
1 3 0 1 0 0 1 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 1 0 1 1 0 1 1 0 1 1 0 1 1 0 0 1 1 0 1 1 0 1 1 0 1 1 0 1 1 0	, -,	1111 0		111		10 0	0	0		1			0	0			0	_	0	0	0					
0 1 0 1 0 1 2 0 2 1 0 0 0 0 0 1 2 0 1 1 1 0 1 0 0 1 0 1 0 1 1 1 0 1 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 1 1 1 0 <td< td=""><td></td><td>1</td><td></td><td></td><td></td><td>1</td><td>0</td><td>0 11</td><td>_</td><td></td><td>-</td><td>_</td><td>4</td><td>0</td><td>0</td><td>5</td><td>5</td><td>-</td><td>0</td><td>0</td><td>0</td><td>_</td><td></td><td></td></td<>		1				1	0	0 11	_		-	_	4	0	0	5	5	-	0	0	0	_				
12 0 0 0 0 0 1 0 1 1 1 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0		0 11					0	0	11	0			7			1	2		0	2	0					
12 100 17 100 1 0 100 0 <td>0 1</td> <td>111. 1</td> <td></td> <td></td> <td></td> <td>0</td> <td>0</td> <td>om</td> <td></td> <td>0</td> <td></td> <td></td> <td>0</td> <td>11</td> <td></td> <td>0</td> <td>1</td> <td>_</td> <td>0</td> <td>5</td> <td>0</td> <td></td> <td></td> <td></td>	0 1	111. 1				0	0	om		0			0	11		0	1	_	0	5	0					
	- u	2	111		MA	0	4	0	W//	0	-		0	1	0	0	0		10	0	0	_				
	2 0	7	11			0	0	0 11		7	_	-	0	0	11 0	0	0		0	0	0					
Who 10 10 100 100 10 0 5 1 5 5 0 10 10 5 0 10	101	0 11		0 ////	11/1	0 11	0	0	111	0	_	_	0	-	0	0	111 0	11	0	0	0 11					
	: :	0 111			VIII .	11	0	100	-		-	5		5	_	0	110	5		0	0111			1		

When necessary the standard L-dopa regimen was modified to obtain the best possible clinical response. Patients were then switched to Madopar HBS in equivalent doses with adjustments of dose size and frequency until sufficient clinical effect had been achieved. In all patients 100 mg of standard L-dopa were added to their first morning dose and in two cases a further dose of 50 mg of conventional L-dopa was needed in the afternoon. Responders were followed as out-patients with bimonthly controls and clinical assessment was based on the patient's self-scoring on-off diary which was kept throughout the trial.

277

Figure 1

RESULTS

8 responders were treated with Madopar HBS for a mean period of 241 days. The mean daily dose of Madopar HBS was 900 mg averaging an increase of 64 per cent over the previous mean standard L-dopa of 550mg in this group of 8. Dosing frequency and dose intervals were only slightly different from standard L-dopa treatment (see Table 2).

Table 2

Madopar HBS in advanced P.O.-results in responders N = 8

	conventional L-dopa	Madopar HBS
daily dose No. of doses dose interval HRS "on" duration of HBS treatment	550 (350-800) mg 5,6 (4-8)/d 3,1 (2-4) hrs 7,7 (6-10)	900(400-1800)mg 5(3-8)/d 3,5(3-4,5) hrs 12,5(10-14) 241(97-414)days

+ Columbia University Parkinson Scale (CURS) and Northwestern Disability Scale (NUDS).

Response fluctuations were considerably improved with a reduction of end-of-dose effects and an increase of total daily "on" time in all responders (see Table 2). Figure 1 gives an example of one responder's self-scoring on-off diary showing increased "on" time during one week of HBS treatment as compared to one week on standard L-dopa. Biphasic dyskinesias disappeared in three or five patients and were reduced in two, where there was only one episode after each morning dose (see Table 3).

Table 3

Madopar HBS in advanced P.D.-results in responders No. of patients improved with Madopar HBS

End of dose effects (N=8)	8
Nocturnal immobility (N≏8)	4
Biphasic dyskinesia (N=5)	5
Off-period dystonia (N=2)	2

In all four patients with marked-time disabilities there was improvement of nocturnal akinesia. 2 patients of this group had had off-period dystonia which was abolished when on Madopar HBS.

5 of the ll patients participating in the trial stopped Madopar HBS after a mean duration of 65 days. Three patients did not finish their adjustment phase (early drop-outs after 5,6 and 18 days, respectively) due to prolonged off-periods. Inspite of high total daily doses of Madopar HBS up to the twofold of prior conventional L-dopa therapy no sufficient clinical effect could be achieved. 2 of the 8 responders stopped Madopar HBS after 93 and 204 days, respectively,due to the unpredictability of onset and duration of response to Madopar HBS and to increases peak-dose chorea paralleling the prolonged "on" periods (see Table 4).

Table 4

Madopar HBS in advanced P.D./ reasons for treatment failures

(N = 5)	
Duration of HBS	65(5-204)days
Reasons for stopping HBS	
 prolonged off-periods 	3 pts.
 unpredictable response 	2 pts.
 increased peak dose AIM's 	2 pts.

1 ...

E)

One of these patients also reported outbursts of disabling peak-dose choreic movements. In both patients peak-dose choreic movements led to functionally useless "on" periods and therefore to discontinuation of Madopar HBS. In 6 of the 8 responder patients there was no or only slight increase of peak-dose dyskinesias.

DISCUSSION

The sustained-release principle of Madopar HBS may lead to a reduction of dose-dependent fluctuations in motor performance, increase in noc-turnal mobility and decrease in biphasic as well as off-period dystonia. The observed increase in the total daily dose of L-dopa with Madopar HBS treatment corresponds to the decreased bioavailability of Madopar HBS which has been shown to be about 60 per cent of conventional L-dopa (Crevoisier et al, 1985). It is not always possible to overcome this problem by increasing the dose of sustained-release L-dopa: in 3 nonresponders no clinical benefit could be achieved despite of an increase of 100 per cent over the previous standard L-dopa dose. Increased peakdose chorea as observed in several patients of this study, particulary in the afternoon, may represent an "overlap effect" (Eckstein et al, 1973). It can be a reason for treatment failure by rendering "on" neriods functionally useless as seen in 2 of the 8 responders of this series. The main disadvantage of sustained-release L-dopa in this study was the unpredictability of onset and duration of clinical effects. The controlled-release principle of Madopar HBS is based on a continuous release of L-dopa while the capsule remains floating in the stomach ous release of L-oopa while the capsule remains floating in the stomach for prolonged periods of time (Poewe et al, 1986). As the absorption site for L-dopa is the proximal small intestine the sustained-release principle of Madopar HBS can be influenced by erratic gastric activity (Nutt, 1987). Individual differences in gastric acti-vity may be responsible for the fact that not all patients complain about this problem. For a reliable and rapid "switch on" in the morning all patients needed conventional L-dopa in addition to their first dose of Madopar HBS. 4 of the responders took further so-called "back-up" doses of conventional L-dopa when needed, especially in the after-noon. Despite of the various shortcomings the results of this study show that Madopar HBS can be a useful alternative in the treatment of

REFERENCES

Chouza,C., Romero,S., De Medina.O. et al.(1985): Results of the substitution of Madopar Standard by Madopar HBS in parkinsonians with fluctuations in the therapeutic effect. <u>Int.Workshop on the</u> <u>On-Off-Phenomenon in Parkinson's Disease.</u> Nov.14-16

Parkinson patients with the L-dopa long-term syndrome.

Crevoisier, C., Hoevels, B., DaPrada, M. (1985): Bioavailability of Madopar HBS in healthy volunteers. Int. Workshop on the On-Off-Phenomenon in Parkinson's Disease. Nov.14-16 Eckstein, B., Shaw, K., Stern, G. (1973): Sustained-release levodopa in parkinsonism. Lancet 1. 431-432 Marsden, C. D., Parkes, J.D. (1976): "On-off" effects in patients with Barkinson disease on phenois lancet theorem. In the second

Parkinson's disease on chronic levodopa therapy. Lancet 1,292-296 Marsden,C.D., Parkes,J.D., Quinn,N. (1982): Fluctuations of disability

in Parkinson's disease: clinical aspects. In Movement Disorders,

eds.C.D.Marsden. S.Fahns, pp.96-122 London:Butterworth Scientific Nutt.J.G.(1987): Pharmacokinetics of Levodopa. In <u>Handbook of Parkin-</u> son's Disease. Marcel Dekker Inc., ed.W.C.Koller,pp.339-354 New York-Basel

Poewe,W.H., Lees,A.J., Stern,G.M.(1986): Ireatment of Motor fluctuat-ions in Parkinson's disease with an oral sustained-release preparation of L-dopa:clinical and pharmacokinetic observations. Clin.Neuropharmacol. 9, 430-439

Quinn, N., Parkes, J. D., Marsden, C.D. (1984): Control of on/off phenomenon by continuous intravenous infusion of levodopa. <u>Neurology</u> 34,1131-36 winne,U.K.(1985): Madopar HBS in the long-term treatment of parkinsonian patients presenting fluctuations in disability. Int.Workshop on the On-Off-Phenomenon in Parkinson's Disease, Nov.14-16


NEW TRENDS IN CLINICAL NEUROPHARMACOLOGY

Calcium antagonists, acute neurology, headache and movement disorders

Proceedings of the Vth European Workshop on Clinical Neuropharmacology, Bratislava, July 6–8, 1987

Edited by DANIEL BARTKO PETER TURČÁNI GERALD STERN

John Libbey LONDON PARIS



British Library Cataloguing in Publication Data European Workshop on Clinical Neuropharmacology (5th: 1987: Bratislava, Czechoslovakia) New trends in clinical neuropharmacology 1. Man. Nervous system. Drug Therapy I. Title II. Bartko, Daniel III. Turčáni, Peter IV. Stern, Gerald V. Series 616 8'0461 616.8'0461

ISBN 0-86196-146-3

First published in 1988 by John Libbey & Company Ltd 80/84 Bondway, London SW8 1SF, England. (01) 582 5266 John Libbey Eurotext Ltd 6 rue Blanche, 92129 Montrouge, France. (1) 47 35 85 52

New trends in clinical neuropharmacology : calcium antagonists, acute neurology, headache, and movement disorders : proceedings of the Vth European Workshop on Clinical Neuropharmacology, Bratislava, July 6-8, 1987

	Author(s):	Bartko, Daniel
		Turcáni, Peter
		Stern, Gerald, 1930-
		European Workshop on Clinical Neuropharmacology (5th 1987 Bratislava Czechoslovakia)
13	Title(s):	New trends in clinical neuropharmacology : calcium antagonists, acute neurology, headache, and movement disorders : proceedings of the Vth European Workshop on Clinical Neuropharmacology, Bratislava, July 6-8, 1987 / edited by Daniel Bartko, Peter Turčáni, Gerald Stern.
	Series:	Current problems in neurology, ; 7 ISSN 0268-6252
	Country of Publication:	England
	Publisher:	London : John Libbey, 1988.
	Description:	vi, 348 p. ∴ ill.
	Language:	English
	ISBN:	9780861961467 0861961463
	MeSH:	Calcium Channel Blockers/therapeutic use* Cerebrovascular Disorders/drug therapy* Headache/drug therapy* Movement Disorders/drug therapy*
	Publication Type(s):	Congresses
	Notes:	Includes bibliographical references.
	NLM ID:	9015503 [Book]